secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001564590-21-042877
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch transfers FIN-524 ulcerative colitis program to Takeda for clinical development
--------------------------------------------------------------------------------

- Amendment (Aug 9, 2021) transfers primary development & regulatory responsibility for FIN-524/TAK-524 to Takeda ahead of Phase 1.
- Finch received $10M upfront & $4M in milestones; eligible for up to $176M additional plus mid-to-high single-digit royalties.
- Finch will provide technical support through Phase 1; joint Crohn's disease discovery continues.
- TAK-524 is an orally administered consortia candidate targeting ulcerative colitis via immune modulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000156459021042877/0001564590-21-042877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000156459021042877/fnch-8k_20210810.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-042877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer